Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Trastuzumab Rezetecan-based Therapy for Brain Metastases in HER2-Positive Breast Cancer (Phase II)
ChiCTR2600120221Phase 2Not yet recruiting
- Sponsor
- Chongqing University Cancer Hospital
- Start
- Mar 2026
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of trastuzumab rezetecan in breast cancer and brain metastases (4 arms), sponsored by Chongqing University Cancer Hospital. Primary endpoint: Central Nervous System - Objective Response Rate. Planned start Mar 2026; status: not yet recruiting.
02
Drugs
trastuzumab rezetecan
03
Conditions
breast cancerbrain metastases
Beyond the preview
Go deeper on ChiCTR2600120221.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2600120221.